TREATMENT WITH LIPOSOMAL AMPHOTERICIN-B OF A CHILD AFFECTED WITH DRUG-RESISTANT VISCERAL LEISHMANIASIS

被引：13
|
作者：
GIACCHINO, R
GIAMBARTOLOMEI, G
TASSO, L
TIMITILLI, A
CASTAGNOLA, E
BRISIGOTTI, M
MICALIZZI, C
机构：
[1] G GASLINI CHILDRENS HOSP,DEPT PATHOL,GENOA,ITALY
[2] G GASLINI CHILDRENS HOSP,DEPT HAEMATOL,GENOA,ITALY
来源：
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE | 1993年 / 87卷 / 03期
关键词：
D O I：
10.1016/0035-9203(93)90141-C
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
[No abstract available]
引用
收藏
页码：310 / 310
页数：1
相关论文
共 50 条
  • [21] AMPHOTERICIN-B FOR VISCERAL LEISHMANIASIS RESISTANT TO PENTAVALENT ANTIMONIAL DRUGS IN AIDS
    RODILLA, F
    MAGRANER, J
    AZNAR, J
    OROVITG, F
    ALCACER, F
    COLOMINA, J
    FERRIOLS, F
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (11) : 1305 - 1305
  • [22] ARE INCREMENTAL DOSES OF AMPHOTERICIN-B REQUIRED FOR THE TREATMENT OF VISCERAL LEISHMANIASIS
    THAKUR, CP
    SINHA, GP
    BARAT, D
    SINGH, RK
    ANNALS OF TROPICAL MEDICINE AND PARASITOLOGY, 1994, 88 (04): : 365 - 370
  • [23] EFFICACY OF LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS IN PATIENTS COINFECTED WITH THE HUMAN-IMMUNODEFICIENCY-VIRUS
    TORRECISNEROS, J
    VILLANUEVA, JL
    CLINICAL INFECTIOUS DISEASES, 1995, 20 (01) : 191 - 191
  • [24] Visceral leishmaniasis treated with liposomal amphotericin B
    Catania, S
    Aiassa, C
    Tzahtzoglou, S
    Catania, N
    Tucciarone, L
    Antimi, A
    Ragni, G
    Clerico, A
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1999, 18 (01) : 73 - 75
  • [25] Liposomal amphotericin B to treat visceral leishmaniasis
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    REVISTA IBEROAMERICANA DE MICOLOGIA, 2021, 38 (02): : 101 - 104
  • [26] Reversible Ototoxicity: A Rare Adverse Reaction of Liposomal Amphotericin-B Used for the Treatment of Antimony-Resistant Visceral Leishmaniasis in an Elderly Male
    Das, P. C.
    Kandel, Ramesh
    Sikka, Kapil
    Dey, A. B.
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2014, 7 : 63 - 66
  • [27] US Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
    Meyerhoff, A
    CLINICAL INFECTIOUS DISEASES, 1999, 28 (01) : 42 - 48
  • [28] Treatment of visceral leishmaniasis with liposomal amphotericin B in three immunocompromised patients
    Rodríguez-Wilhelmi, P
    Panizo, C
    Ruza, E
    Rocha, E
    MEDICINA CLINICA, 2001, 116 (01): : 37 - 38
  • [29] SUCCESSFUL TREATMENT OF DISSEMINATED CANDIDIASIS RESISTANT TO AMPHOTERICIN-B BY LIPOSOMAL AMPHOTERICIN-B - A CASE-REPORT
    GOKHALE, PC
    BARAPATRE, RJ
    ADVANI, SH
    KSHIRSAGAR, NA
    PANDYA, SK
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1993, 119 (10) : 569 - 571
  • [30] EFFICACY OF INTERMITTENT LIPOSOMAL AMPHOTERICIN-B IN THE TREATMENT OF VISCERAL LEISHMANIASIS IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS
    LAGUNA, F
    TORRECISNEROS, J
    MORENO, V
    VILLANUEVA, JL
    VALENCIA, E
    CLINICAL INFECTIOUS DISEASES, 1995, 21 (03) : 711 - 712
12345